Jpmorgan Chase & CO Actinium Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 123,831 shares of ATNM stock, worth $152,312. This represents 0.0% of its overall portfolio holdings.
Number of Shares
123,831
Previous 13,690
804.54%
Holding current value
$152,312
Previous $25,000
524.0%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ATNM
# of Institutions
70Shares Held
7.94MCall Options Held
59.6KPut Options Held
4.8K-
Black Rock Inc. New York, NY1.88MShares$2.31 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.62MShares$1.99 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA688KShares$846,0590.0% of portfolio
-
State Street Corp Boston, MA621KShares$763,9220.0% of portfolio
-
Acadian Asset Management LLC Boston, MA499KShares$614,0890.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $31M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...